Cross-sectional study of hepatitis B virus infection in rural communities, Central African Republic

  • Narcisse P Komas3Email author,

    Affiliated with

    • Ulrich Vickos3,

      Affiliated with

      • Judith M Hübschen4,

        Affiliated with

        • Aubin Béré3,

          Affiliated with

          • Alexandre Manirakiza3,

            Affiliated with

            • Claude P Muller4 and

              Affiliated with

              • Alain Le Faou3, 4

                Affiliated with

                BMC Infectious Diseases201313:286

                DOI: 10.1186/1471-2334-13-286

                Received: 18 February 2013

                Accepted: 18 June 2013

                Published: 24 June 2013

                Abstract

                Background

                As most data on hepatitis in resource-poor countries relate to urban communities, surveys in the rural environment are necessary to determine the ‘true’ prevalence of these viral infections. We undertook a survey to determine the prevalence of hepatitis B virus (HBV) infection in an apparently healthy rural population in the Central African Republic (CAR).

                Methods

                The cross-sectional study was based on dried blood spots (DBS) from 273 people recruited in four prefectures (Lobaye, Nana-Mambéré, Ouham and Ouaka). Eluates from DBS were tested with commercial ELISA kits to detect markers of HBV infection. DBS were directly used for DNA extraction, followed by PCR and genotyping based on preS/S gene sequences.

                Results

                The overall prevalence of HBc antibodies was 27.1% (Lobaye 29%, Nana-Mambéré 28%, Ouaka 29% and Ouham 23%) and that of HBsAg was 10.6% (Lobaye 9%, Nana-Mambéré 9%, Ouaka 19% and Ouham 8%), with no statistically significant difference among the surveyed communities. Nineteen sequences obtained from 74 anti-HBc-positive patients all belonged to genotype E. Risk factor analysis of HBV infection pointed to sexual transmission of the virus.

                Conclusion

                The prevalence of HBV is high in rural communities in the CAR and comparable to that observed in urban areas. In addition, genotype E is prevalent in these areas. These findings underline the importance of instituting a programme of active HBV surveillance and vaccination of the population.

                Keywords

                Hepatitis B virus HBV Central African Republic HBV risk factors HBV prevalence Rural community HBV genotyping

                Background

                Despite the availability of an effective vaccine, infection with hepatitis B virus (HBV) remains a major worldwide health problem: over 2 billion people have been in contact with the virus, and there are 400 million chronic carriers and 1 million deaths per year [1]. It is hyperendemic in sub-Saharan Africa and Asia [25]. HBV is the type species of the Hepadnaviridae family and is categorized into eight genotypes (A to H) on the basis of a divergence of more than 8% in the entire nucleotide sequence of the viral DNA. Recently, two additional genotypes, I and J, were tentatively proposed [6, 7].

                There are several routes of HBV transmission in sub-Saharan Africa. The highest prevalence is reported in 20–40-year-olds, and horizontal transmission in early life, as a consequence of close family contact, is the most common route of infection [8, 9]. In the Central African Republic (CAR), E is the prevalent genotype among HBV-infected patients, although genotypes A1, D4 and a genotype E and D recombinant have also been reported [10].

                Most studies of the seroprevalence of HBV in the CAR have been conducted in urban areas, mainly Bangui [1012], with only a few in rural areas [13, 14]. In order to obtain a more precise idea of the impact of HBV infection in rural communities, we performed a survey in four prefectures of the country.

                Methods

                Study population

                A cross-sectional study was carried out between November 2007 and April 2008. On the basis of an estimated HBsAg prevalence of 13% and a precision of 4%, we calculated that a minimum of 271 patients were needed. Hence, dried blood spots (DBS) were collected as previously described [11] from 273 apparently healthy individuals in the prefectures of Ouaka (n = 48), Ouham (n = 75), Nana Mambéré (n = 75) and Lobaye (n = 75). The inhabitants of the four prefectures represent one tenth of the rural population of the CAR. The area selected for sampling in each prefecture was representative of at least half (Lobaye), a third (Nana-Mambéré and Ouaka) and a quarter (Ouham) of the total population. The people living in the study areas were informed of the purpose of the study well before sample collection. Participants were recruited on a voluntary basis. To avoid collecting blood from several members of the same family, donors were selected randomly from among volunteers in each family and from among all those free of symptoms of hepatitis. Most of the participants were illiterate, and several socio-professional groups were represented. Once air-dried, the filter papers were sealed in plastic bags, taken to the laboratory at the Institut Pasteur de Bangui and stored at -20°C with a desiccant until testing.

                A questionnaire on socio-demographic characteristics, such as gender, age, place of residence, education, marital status, parity, socioeconomic level and sexual practices, was completed for identification of risk factors for HBV infection. Each participant or his or her parents signed an informed consent form and was informed about the serology results. The study protocol was approved by the Scientific Committee of the Faculty of Health Sciences of the University of Bangui, CAR.

                Serological tests

                Blood was eluted from DBS as previously described [11]. DBS were screened with the HBsAg Version 3, anti-HBc (total) and anti-HBc (IgM) antibody kits (Abbott-Murex Biotech Ltd, Dartford, Kent, United Kingdom). Serological tests were performed and interpreted according to the manufacturer’s recommendations.

                Detection of HBV DNA and HBV genotyping

                DNA was extracted from the DBS with the QIAamp DNA Blood Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s protocol. The extracted DNA was used for PCR amplification and sequencing as previously described [15]. Partial sequences covering the preS and S gene regions were aligned and compared with SeqScape v2.5 (Applied Biosystems, Nieuwerkerk, Netherlands) and BioEdit version 7.0.9.0 [16]. Phylogenetic trees were constructed with MEGA4 software [17] and the neighbour-joining and Kimura 2-parameter methods. Sequences representative of known genotypes and sub-genotypes and the most similar previously published sequences identified by BLAST were downloaded from GenBank and included in the analysis. The nucleotide sequence data reported in this paper are available under GenBank accession numbers JQ972779–JQ972830.

                Statistical analysis

                Stata 11.0 software was used to determine the prevalence rates of HBV; the Fisher exact test was used to compare variables and the association between HBV positivity and risk factors such as marital status, years since first sexual intercourse, use of condoms, number of sexual partners, socio-professional activity and previous risk behaviour. These risk factors of HBV infection were assessed by estimating odds ratios. Confidence intervals were calculated at 95%. Statistical significance was assessed at p < 0.05.

                Results

                Serology and geographical distribution of hepatitis B virus in the four prefectures

                In the tested population, comprising 173 (63.7%) females and 100 (36.6%) males aged 2–67 years (mean, 27 years, SD ± 15), 74 people (27.1%) had anti-HBc antibodies, indicating that a high proportion of these rural populations had been exposed to HBV. The population prevalence was estimated as 24.2% by standardizing the seroprevalence results obtained according to the gender and age group distribution of the CAR population. HBsAg was found in 29 (10.6%) donors, and 7 (24.1%) had been recently infected or presented with acute viral hepatitis B (anti-HBc IgM antibody positive). Five were aged 17–25 years and two were more than 25 years old. Forty-five (16.5%) individuals were positive for anti-HBc but negative for HBsAg.

                The prevalence of HBV infection was higher in males than in females over 16 years of age (p = 0.03, Table 1). Although no statistically significant differences in the overall HBV and HBsAg prevalence in the four prefectures were observed, a higher HBsAg rate was found in Ouaka than in the other three locations (Figure 1).
                Table 1

                HBV positivity by sex and age among 273 donors in rural regions of four prefectures of the Central African Republic

                Age (years)

                Male

                Female

                Total

                 

                n positive (Total)

                % of *HBV+ (95% CI)

                n positive (Total)

                % of *HBV+ (95% CI)

                n positive (Total)

                % *HBV+(95% CI)

                0–15

                5 (29)

                17.8 (3.5–31.0)

                5 (28)

                17.8 (3.7–32.0)

                10 (57)

                17.5 (8.4–32.3)

                16–25

                18 (40)

                45.0 (29.6–60.4)

                20 (58)

                34.5 (22.2–46.7)

                38 (98)

                38.8 (27.4–53.2)

                > 25

                8 (31)

                25.8 (10.4–41.2)

                18 (87)

                20.7 (12.2–29.2)

                26 (18)

                22.0 (14.4–32.3)

                All

                31 (100)

                31.0 (21.1–44.0)

                43 (173)

                25.0 (18.0–33.5)

                74 (273)

                27.1** (21.3–34.0)

                *At least one marker (HBsAg or anti-HBc antibody).

                **The estimated population prevalence after taking into account the gender and age group distribution of the CAR is 24.2%.

                http://static-content.springer.com/image/art%3A10.1186%2F1471-2334-13-286/MediaObjects/12879_2013_2490_Fig1_HTML.jpg
                Figure 1

                Geographical location of the four surveyed prefectures and their HBsAg and HBc antibody prevalence.

                Risk factors for HBV infection

                No statistically significant association was found between HBV infection and socio-demographic characteristics. However, monogamous males had a slightly higher HBV prevalence (40% or 16/40) than single or polygamic males (24% or 12/49) (Table 2) (p value = 0.18). Sexual behavior (years since first sexual intercourse, use of condoms and number of sexual partners) was only moderately associated with HBV infection. The only profession associated with HBV infection was small trader (Table 2). Although the HBsAg prevalence seems to be higher in the Ouaka prefecture than in the three other prefectures no particular predisposing risk factors were identified, maybe because of the limited number of positive people.
                Table 2

                Risk factors for HBV infection

                Variable

                n

                *HBV+ (%)

                Odds ratio

                95% CI

                Marital status

                  ○ Male

                    

                    • Monogamous marriage

                40

                16 (40.0)

                1.00

                 

                    • Single

                49

                12 (24.5)

                0.51

                0.20–1.27

                    • Polygamous marriage

                11

                03 (27.0)

                0.56

                0.12–2.44

                  ○ Female

                    

                    • Monogamous marriage

                81

                22 (27.1)

                1.00

                 

                    • Single

                73

                16 (22.0)

                0.75

                0.35–1.57

                    • Polygamous marriage

                19

                05 (26.3)

                0.95

                0.30–2.97

                Years since first sexual intercourse

                  ○ ≤ 10

                99

                26 (26.3)

                1.00

                 

                  ○ 11–20

                48

                17 (35.4)

                1.53

                0.73–3.23

                  ○ 21–30

                31

                11 (35.5)

                1.54

                0.65–3.65

                  ○ > 30

                28

                06 (21.4)

                0.76

                0.27–2.09

                Use of condoms

                  ○ Yes

                19

                06 (31.6)

                1.00

                 

                  ○ No

                227

                64 (28.2)

                1.12

                0.40–3.10

                Number of sexual partners

                  ○ One

                6

                02 (33.3)

                1

                 

                  ○ Two or more

                102

                32 (31.4)

                1.20

                0.21–6.83

                Socio-professional activity

                  ○ Civil servant

                24

                05 (20.8)

                1.00

                 

                  ○ Small trader

                10

                05 (50.0)

                3.80

                0.78–18.50

                  ○ Farmer

                63

                19 (30.2)

                1.64

                0.53–5.04

                  ○ Student

                74

                22 (29.7)

                1.60

                0.53–4.84

                  ○ Unemployed

                28

                05 (17.8)

                0.80

                0.20–3.28

                  ○ Others**

                65

                18 (27.7)

                1.45

                0.47–4.48

                Previous risk behaviour

                  ○ None

                71

                22 (31.0)

                1.00

                 

                  ○ Scarification

                169

                44 (26.0)

                0.78

                0.42–1.44

                  ○ Surgery

                47

                12 (25.5)

                0.76

                0.33–1.74

                  ○ Blood transfusion

                30

                04 (13.3)

                0.34

                0.10–1.10

                  ○ Tattooing

                31

                09 (29.0)

                0.91

                0.36–2.29

                  ○ Dental surgery

                33

                10 (30.3)

                0.96

                0.39–2.37

                *At least one marker (HBsAg or anti-HBc antibodies).

                **Others: carpenter, apprentice, driver, night watchman, craftsman.

                Sequence analysis and genotyping

                Sequence information was obtained for 19 of the 74 anti-HBc antibody-positive samples tested, with 14 sequences from HBsAg-positive samples and 5 from people positive only for antibodies to HBc. All the sequences belonged to genotype E and were similar to strains from CAR, Cameroon, Guinea and Niger (Figures 2A and 2B).
                http://static-content.springer.com/image/art%3A10.1186%2F1471-2334-13-286/MediaObjects/12879_2013_2490_Fig2_HTML.jpg
                Figure 2

                Phylogenetic tree based on 763 nucleotides of the preS (A) (13 strains) and 884 nucleotides of the S (B) (19 strains) gene regions of HBV strains from the Central African Republic (marked with a black dot) and reference strains of recognized and proposed genotypes and closest BLAST fits; GenBank accession numbers are indicated in the tree. Only bootstrap values (n = 1000) ≥ 70 are shown.

                Discussion

                The overall prevalence of HBV detected in the present study was slightly higher than that reported in blood donors in Burkina Faso (14.96%) [18], lower than those reported in pregnant women in the United Republic of Tanzania (56.2%) [19] and in Ghana (67.1%) [20], in a cohort of students in Bangui (42.3%) [11], in blood donors in Cameroon (86.8%) and Sudan (36%) [21, 22] and in the staff of a public hospital in Luanda (79.7%) [23]. The diversity of the observed prevalence is probably due to the diversity of patients and population groups and differences in sampling method, test kit sensitivity and specificity or differences between rural areas and large cities. In large cities, population movement and a permissive lifestyle increase the risk for exposure to this disease.

                Dried blood spots are now commonly used for serology and molecular biology testing. The only problem encountered so far is a slightly lower sensitivity, although reliable results are obtained. The technique permits surveys to be conducted in remote areas, as it requires little equipment, the cost of sampling is low, and it is widely accepted as it is almost painless [11].

                A better estimate of the prevalence of HBV infection in rural areas throughout the country would have been obtained if we had surveyed all 16 prefectures; however, this was not possible because of the absence of practicable roads and wide insecurity. Nevertheless, the prevalences of HBV in the four prefectures studied (Lobaye 29%, Nana-Mambéré 28%, Ouaka 29% and Ouham 23%) are similar and lower than the only previous prevalence data published more than two decades ago in the prefecture of Ouham-Pendé (61% in 1984 and 48% in 1988) [13]. Similarly, the HBsAg prevalence was lower than in Ouham-Pendé (20.9%) [14] in all prefectures except for Ouaka (19%, Figure 1). The high HBsAg prevalence in Ouaka prefecture was not statistically different from that in the other three prefectures, probably because of the relatively small number of people investigated. Individuals positive for antibodies against HBc but HBsAg negative were found commonly (16.5%), and viral DNA was detected in five. Thus, the number of patients with active HBV infection is underestimated if only HBsAg prevalence is considered. Inability to detect HBsAg may be due to a mutation (G145R for example, which abolishes HBsAg specificity); however, such mutants are unlikely to be selected by vaccination [24], which in the CAR is given only to young children within the expanded programme of immunization (EPI) . A high prevalence of HBV DNA in the absence of HBsAg was previously described among students in Benin, which was not explained by mutations in the S gene sequence [25], and has also been observed previously in the CAR [10]. A certain characteristic of the population that favours occult infection is a possibility and requires additional investigation [26]. Occult infections are often overlooked, as these patients are considered uninfected on the basis of HBsAg test results. As a consequence, a diagnosis of chronic hepatitis B should systematically include screening for HBV DNA when antibodies to HBc are present and HBsAg is not.

                Analysis of the socio-demographic data did not reveal any significant risk factor for acquiring HBV infection in rural areas of the CAR. Nevertheless, small traders were more often affected than people in other professions (50%); sexual practices (30–40%), tattooing (29%), blood transfusion (13%) and dental surgery (10%) were other possible risk factors. These percentages were much lower than in a cohort of students in Bangui [11] (sexual practices, 38.2–53.3%; tattooing, 42.4%; blood transfusion, 39.4%; dental surgery; 38%). It is possible that other unknown or unstudied risk factors contribute to the transmission of HBV in rural CAR, and large-scale studies should be performed, including more risk factors.

                In contrast to other studies [4, 21, 23] that showed a certain diversity of HBV genotypes in Central African countries, this study confirms that genotype E is highly predominant, not only in Bangui [10] but also in rural areas of the CAR, supporting the hypothesis that this country is part of the vast genotype E crescent, spanning Africa from Senegal to Angola [25]. Characterization of HBV nucleotide sequences from a large sampling in rural CAR should be undertaken to better evaluate the genetic variability of this virus in these areas.

                Conclusion

                HBV infection is a major health issue in the CAR, as shown by high prevalence rates. The prevalence in the four prefectures is close to that in Bangui, and only genotype E sequences were found. This high prevalence confirms that HBV is responsible for high rates of morbidity and mortality in CAR. The results underline the necessity for adult vaccination against hepatitis B in addition to HBV vaccination included in the EPI since November 2008.

                Abbreviations

                Anti-HBc Ab: 

                Anti-hepatitis B core antibody

                CAR: 

                Central African Republic

                DBS: 

                Dried blood spots

                EPI: 

                Expanded Programme for Immunization

                HBsAg: 

                Hepatitis B surface antigen

                HBV: 

                Hepatitis B virus

                PCR: 

                Polymerase chain reaction.

                Declarations

                Acknowledgements

                The authors wish to thank Professor Elisabeth Heseltine for critical reading of the manuscript and help in revising the written English and Aurélie Sausy for help in performing the molecular biology experiments. We also thank the rural communities of Lobaye, Nana Mambéré, Ouaka and Ouham for their cooperation and are grateful to the health agents at the hospitals of Mbaïki (Lobaye), Bambari (Ouaka), Bouar (Nana Mambéré) and Bossangoa (Ouham) for their help in blood sample collection.

                Authors’ Affiliations

                (1)
                Viral Hepatitis Laboratory, Institut Pasteur de Bangui
                (2)
                Institute of Immunology, Centre de Recherche Publique de la Santé / Laboratoire National de Santé
                (3)
                Epidemiology service, Institut Pasteur de Bangui
                (4)
                New affiliation: EA 3452 CITHEFOR ; Faculté de Pharmacie, Université de Lorraine

                References

                1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97–107.PubMedView Article
                2. Garshau W, Mohammed I: Hepatitis B viral markers in Nigerian patients with primary liver carcinoma. Trop Geogr Med 1991, 43:64–67.
                3. Kramvis A, Kew MC: Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 2007, 37:S9-S19.PubMedView Article
                4. Makuwa M, Souquière S, Telfer P, Apetrei C, Vray M, Bedjabaga I, Mouinga-Ondeme A, Onanga R, Marx PA, Kazanji M, Roques P, Simon F: Identification of hepatitis B virus subgenotype A3 in rural gabon. J Med Virol 2006, 78:1175–1184.PubMedView Article
                5. Nwokediuko SC: Chronic hepatitis B: management challenges in resource-poor countries. Hepat Mon 2011, 11:786–793.PubMed
                6. Lin CL, Kao JH: The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011,26(Suppl 1):123–130.PubMedView Article
                7. Olinger CM, Jutavijittum P, Hübschen JM, Yousukh A, Samountry B, Thammavong T, Toriyama K, Muller CP: Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis 2008, 14:1777–1780.PubMedView Article
                8. Dumpis U, Holmes EC, Mendy M, Hill A, Thursz M, Hall A, Whittle H, Karayiannis P: Transmission of hepatitis B virus infection in gambian families revealed by phylogenetic analysis. J Hepatol 2001, 35:99–104.PubMedView Article
                9. Szmuness W, Prince AM, Hirsch RL, Brotman B: Familial clustering of hepatitis B infection. N Engl J Med 1973, 289:1162–1166.PubMedView Article
                10. Bekondi C, Olinger CM, Boua N, Talarmin A, Muller CP, Le Faou A, Venard V: Central African Republic is part of the West-African hepatitis B virus genotype E crescent. J Clin Virol 2007, 40:31–37.PubMedView Article
                11. Komas NP, Baï-Sepou S, Manirakiza A, Léal J, Béré A, Le Faou A: The prevalence of hepatitis B virus markers in a cohort of students in Bangui, Central African Republic. BMC Infect Dis 2010, 10:226.PubMedView Article
                12. Pawlotsky JM, Bélec L, Grésenguet G, Deforges L, Bouvier M, Duval J, Dhumeaux D: High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. J Med Virol 1995, 46:269–272.PubMedView Article
                13. Bélec L, Gresenguet G, Georges-Courbot MC, Villon A, Martin MH, Georges AJ: Sero-epidemiologic study of several sexually transmitted diseases (including HIV infection) in a rural zone of the Central African Republic. Bull Soc Pathol Exot Filiales 1988, 81:692–698.PubMed
                14. Crovari P, Santolini M, Bandettini R, Bonanni P, Branca P, Coppola RC: Epidemiology of HBV and HDV infections in a rural area of Central African Republic. Prog Clin Biol Res 1991, 364:69–73.PubMed
                15. Olinger CM, Venard V, Njayou M, Bola Oyefolu AO, Maiga I, Kemps AJ, Omilabu SA, Le Faou A, Muller CP: Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa : new subtypes, mix infections and recombinations. J Gen Virol 2006, 87:1163–1173.PubMedView Article
                16. Hall: BioEdit: A user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucl Acids Symp Ser 1999, 41:95–98.
                17. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: molecular evolutionary geneticsanalysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596–1599.PubMedView Article
                18. Nagalo MB, Sanou M, Bisseye C, Kaboré MI, Nebie YK, Kienou K, Kiba A, Dahourou H, Ouattara S, Zongo JD, Simpore J: Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis among blood donors in koudougou (Burkina Faso) in 2009. Blood Transfus 2011, 9:419–424.PubMed
                19. Menendez C, Sanchez-Tapias JM, Kihagwa E, Kahigwa E, Mshinda H, Costa J, Vidal J, Acosta C, Lopez-Labrador X, Olmedo E, Navia M, Tanner M, Rodes J, Alonso PL: Prevalence and mother-to-infant transmission of hepatitis viruses B, C and E in southern Tanzania. J Med Virol 1999, 58:215–220.PubMedView Article
                20. Acquaye JK, Mingle JAA: Hepatitis B viral markers in Ghanaian pregnant women. West Afr J Med 1994, 13:134–137.PubMed
                21. Kurbanov F, Tanaka Y, Fujiwara K, Sugauchi F, Mbanya D, Zekeng L, Ndembi N, Ngansop C, Kaptue L, Miura T, Ido E, Hayami M, Ichimura H, Mizokami M: A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in cameroon. J Gen Virol 2005, 86:2047–2056.PubMedView Article
                22. Mahgoub S, Candotti D, El Ekiaby M, Allain JP: Hepatitis B virus (HBV) infection and recombination between HBV genotypes D and E in asymptomatic blood donors from Khartoum, Sudan. J Clin Microbiol 2011, 49:298–306.PubMedView Article
                23. Valente F, Vieira Do Lago B, Velasco De Castro CA, De Almeida AJ, Gomes SA, Soares CC: Epidemiology and molecular characterization of hepatitis B virus in Luanda, Angola. Mem Inst Oswaldo Cruz, Rio de Janeiro 2010, 105:970–977.View Article
                24. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC: Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990, 336:325–329.PubMedView Article
                25. Mulders MN, Venard V, Njayou M, Edorh AP, Bola Oyefolu AO, Kehinde MO, Muyembe Tamfum JJ, Nebie YK, Maiga I, Ammerlaan W, Fack F, Omilabu SA, Le Faou A, Muller CP: Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. J Infect Dis 2004, 190:400–408.PubMedView Article
                26. Chemin I, Jeantet D, Kay A, Trépo C: Role of silent hepatitis B virus in chronic hepatitis B surface antigen (-) liver disease. Antiviral Res 2001, 52:117–123.PubMedView Article
                27. Pre-publication history

                  1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2334/​13/​286/​prepub

                Copyright

                © Komas et al.; licensee BioMed Central Ltd. 2013

                This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.